KYPROLIS (carfilzomib) for Injection
Kyprolis is a cancer medicine used together with the medicines daratumumab and dexamethasone, or lenalidomide and dexamethasone or with dexamethasone alone, to treat multiple myeloma (a cancer of the bone marrow). Brand Name: KYPROLIS (carfilzomib) for Injection, for intravenous use Initial U.S. Approval: 2012
Home | (carfilzomib) for Injection
Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!
For Indian Patient inquires under NPP.
For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.
KYPROLIS (carfilzomib) for Injection
The FDA approved carfilzomib in July 2012, for use in people with multiple myeloma who have received at least two prior therapies, including treatment with bortezomib and an immunomodulatory therapy (such as lenalidomide) and have demonstrated disease progression on or within 60 days of completion of the last therapy.
KYPROLIS is a proteasome inhibitor indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies including
bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy. Approval is
based on response rate.
A drug used alone or with other drugs to treat adults with multiple myeloma that came back or did not get better after treatment with one or more other therapies. It is also being studied in the treatment of other types of cancer. Kyprolis blocks the action of enzymes called proteasomes, which may help keep cancer cells from growing and may kill them. It is a type of proteasome inhibitor. Also called carfilzomib.
A drug used alone or with other drugs to treat adults with multiple myeloma that came back or did not get better after treatment with one or more other therapies. It is also being studied in the treatment of other types of cancer. Carfilzomib blocks the action of enzymes called proteasomes, which may help keep cancer cells from growing and may kill them. It is a type of proteasome inhibitor. Also called Kyprolis.
Drug (Brand / Generic): KYPROLIS / carfilzomib
Current Indications: multiple myeloma (a cancer of the bone marrow)
Marketed by:: Onyx Pharmaceuticals, Inc.
Approval Date: 2012
Dosage forms and strengths of KYPROLIS (carfilzomib).
Single-use vial: 60 mg sterile lyophilized powder
Find Reference Updates
Alleviare Life Sciences
Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.
Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.
Alleviare India is certified pharmaceutical facilitator / supplier /importer based in india. They are also who GDP certified. One of the pharmaceutical products they offer is “KYPROLIS (carfilzomib) for Injection”.
Confirmation of the order for KYPROLIS (carfilzomib) for Injection will be subject to the submission of a valid doctor’s prescription and, if applicable, an import permit.
We have delivered medicines to following cities in India – Ahmedabad, Aizawal, Aurangabad, Barshi, Bengaluru, Bhopal, Cachar, Chennai, Dibrugarh, Hyderabad, Karungapally, Kohima, Kollam, Kolkata, Mumbai, Meghalaya, Mizoram, Sikkim, Nagpur, New Delhi, Pondichery, Pune, Punjab, Thirunananthapuram, Tripura, Wardha
ALS serves as a facilitator, supplier & exporter in India assisting patients, doctors, and hospitals in importing the prescription medicine brand KYPROLIS (carfilzomib) for Injection. The import process requires a valid prescription and an Import License in the Patient’s Name.
For patients from following foreign countries seeking access to KYPROLIS (carfilzomib) for Injection, they can inquire and find further information by sending their inquiries to ALS.
We have delivered medicines to following countries – Argentina, Australia, Austria, Azerbaijan, Bahrain, Brazil, Bulgaria, Cambodia, Canada, Chile, Colombia, Costa Rica, Croatia, Cyprus, Denmark, Dominican Republic, Estonia, Finland, France, Georgia, Germany, Ghana, Greece, Guatemala, India, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kenya, Kuwait, Latvia, Lebanon, Libya, Lithuania, Malawi, Mexico, Montenegro, Nepal, Netherlands, New Zealand, Nigeria, Norway, Oman, Pakistan, Paraguay, Peru, Poland, Qatar, Romania, Saudi Arabia, Serbia, Singapore, Slovenia, Spain, Sri Lanka, Sweden, Switzerland, United Arab Emirates, United Kingdom, United States, Venezuela, Zimbabwe.
Kindly reach out to us for KYPROLIS (carfilzomib) for Injection price and availability confirmation.
The price of the medicines is the cost set by the manufacturer. In addition, Named Patient support fee, shipping costs and any local tax (if applicable) will apply.